The Effect of Escitalopram on the Pharmacokinetics and Pharmacodynamics of Tramadol in Healthy Subjects
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Escitalopram will be given to a panel of 16 healthy subject for 9 days. On the ninth day a
single dose of tramadol is administered to the subjects and pharmacokinetic(PK) and
pharmacodynamic(PD) measurements are done for the next 24 hours.
It is stated that escitalopram is only a weak inhibitor of CYP2D6 and therefore no effect is
seen in Pk or PK of tramadol